Kymera Therapeutics (KYMR) Current Assets (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Current Assets data on file, last reported at $677.4 million in Q1 2026.

• On a quarterly basis, Current Assets rose 35.23% year-over-year to $677.4 million in Q1 2026; TTM through Mar 2026 was $677.4 million, a 35.23% increase from a year earlier, with the FY2025 full-year figure at $871.2 million, up 70.74% from the prior year.
• Current Assets for Q1 2026 stood at $677.4 million, down from $871.2 million in the prior quarter.
• Over the last five years, Current Assets for KYMR reached as high as $871.2 million in Q4 2025 and fell as low as $375.7 million in Q3 2023.
• Historically, Current Assets has averaged $516.1 million across 5 years, with a median of $501.0 million in 2025.
• Across the five-year window, Current Assets slipped 23.95% in 2023 and surged 70.74% in 2025, its largest moves.
• Year by year, Current Assets stood at $419.4 million in 2022, then slipped by 3.36% to $405.3 million in 2023, then rose by 25.89% to $510.3 million in 2024, then jumped by 70.74% to $871.2 million in 2025, then dropped by 22.24% to $677.4 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $677.4 million in Q1 2026, $871.2 million in Q4 2025, and $528.3 million in Q3 2025.